Lilly/Amylin Submit Exenatide For Diabetes; Could Be Insulin Alternative
Executive Summary
Lilly is positioning the pending type 2 diabetes therapy exenatide for patients on oral agents who might normally be given insulin
You may also be interested in...
Amylin Exenatide NDA Filing Expected Mid-2004; Symlin Launch in Q1
Amylin is eyeing a mid-2004 filing date for its exenatide NDA
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials